Financial insights of BVS

MyFinsight

For the quarter ending 2026-03-28, BVS made $132,089K in revenue. $3,113K in net income. Net profit margin of 2.36%.

Income Statement	2026-03-28	2025-12-31	2025-09-27	2025-06-28
Net sales	132,089	157,900	138,651	147,660
Cost of sales (including depreciation and amortization of 10,087 and 10,265, respectively)	41,320	49,118	44,422	45,570
Gross profit	90,769	108,782	94,229	102,090
Selling, general and administrative expense	78,325	82,757	78,657	79,110
Research and development expense	2,467	3,007	2,923	3,172
Restructuring costs	454	2,235*	-	-
Change in fair value of contingent consideration	-	0*	0	0
Depreciation and amortization	1,107	1,297	1,398	1,439
Impairment of assets	-	0*	0	0
Loss on disposals	0	0	1	-1
Operating income	8,416	19,486	11,252	18,368
Interest expense, net	-4,326	-5,306	-6,177	-7,494
Gain on extinguishment	-	0	-326	-
Other (income) expense	427	-37	-79	-561
Other expense	-3,899	-5,343	-6,582	-8,055
Income (loss) before income taxes	4,517	14,143	4,670	10,313
Income tax expense (benefit), net	571	-3,175	664	1,041
Net income (loss) from continuing operations	-	17,318*	-	-
Loss from discontinued operations, net of tax	-	0*	-	-
Net income (loss)	3,946	17,318	4,006	9,272
(income) loss attributable to noncontrolling interest - continuing operations	-	2,563*	-	-
Loss attributable to noncontrolling interest - discontinued operations	-	0*	-	-
(income) loss attributable to noncontrolling interest	833	-	851	1,813
Net income (loss) attributable to bioventus inc	3,113	14,755	3,155	7,459

Basic EPS	0.05	0.22	0.05	0.11
Diluted EPS	0.04	0.204	0.05	0.11
Basic Average Shares	67,296,336	67,056,726	66,924,682	66,500,433
Diluted Average Shares	70,008,291	72,276,341	68,837,797	68,536,759

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.